Related Experiment Video
Updated: Feb 4, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
High Efficacy of Intravenous Gimatecan on Human Tumor Xenografts
1DRAST, Animal Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy andrea.decesare@istitutotumori.mi.it.
Background/Aim:
The lipophilic, orally bioavailable camptothecin analogue gimatecan is characterized by improved efficacy over conventional camptothecins on human tumor xenografts. Gimatecan produced excellent outcomes orally with prolonged, low-dose, daily treatments. The aim of this study was to assess the antitumor efficacy of i.v. administered gimatecan.
Materials And Methods:
The antitumor activity of gimatecan delivered i.v. q4dx4 was evaluated in nude mice bearing human tumors and compared to clinically available anticancer drugs.
Results:
Intravenous administration of gimatecan showed superior efficacy with remarkable achievements at well tolerated doses. Moreover, prolonged treatments with i.v. administered gimatecan showed efficacy in models of cancer refractory to current therapeutic approaches, like an orthotopic brain tumor.
Conclusion:
Although the oral route is practical for gimatecan administration, the results support the interest in developing a suitable i.v. formulation in an attempt to further exploit the therapeutic potential of the compound.
Related Concept Videos
Self-Efficacy
Imaging Studies V: Intravenous Urography and Retrograde Pyelography
Dose-Response Relationship: Potency and Efficacy
Local Anesthetics: Clinical Application as Intravenous Regional Anesthesia
One of the advantages of...
Tumor Immunotherapy
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

